Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAD1 | O60671 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22717400 | 0.84 | PDE1B (0.47) | GABRA5PDE1APDE1BPDE1C | |
| SCHEMBL22717409 | 0.77 | MAPK1 (0.40) | KDM4CDYRK1AALDH1A1MAPTKMT2A | |
| SCHEMBL1522812 | 0.72 | MIF (0.52) | KDM4CKCNH2DYRK1AKDM4EALDH1A1 | |
| SCHEMBL9042347 | 0.71 | P2RX4 (0.63) | KDM4CMAPK8MAPK9KDM4EALDH1A1 | |
| SCHEMBL2216252 | 0.70 | CYP19A1 (0.70) | KDM4CKCNH2DYRK1AKDM4ETDP1 | |
| SCHEMBL22845222 | 0.68 | REN (0.41) | KDM4CPLK1KCNH2DYRK1AMAPK8 | |
| SCHEMBL15455123 | 0.68 | MAPK8 (0.54) | KDM4CMAPK8MAPK9KDM4EALDH1A1 | |
| SCHEMBL15545756 | 0.68 | PLK1 (0.48) | PLK1KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL22845276 | 0.68 | REN (0.41) | KDM4CPLK1MAPK8MAPK9ALDH1A1 | |
| SCHEMBL24469968 | 0.68 | KDM4C (0.44) | KDM4CKDM4EALDH1A1KMT2AKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | KDM4C 3860/4885DPP4 361/4885PLK1 1122/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | KDM4C 3860/4885DPP4 361/4885PLK1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.